Table 1.
Baseline characteristics of ITT population
| Age, years | |
| Median (range) | 55.0 (35-75) |
| ECOG PS, n (%) | |
| 0 | 39 (76) |
| 1 | 12 (24) |
| 2 | 0 |
| Disease type, n (%) | |
| Invasive carcinoma NOS | 41 (80) |
| Papillary tubular carcinoma | 9 (18) |
| Invasive lobular carcinoma | 1 (2) |
| Time since diagnosis (months) (n = 44) | |
| Minimum | 10 |
| 1st quartile | 24.5 |
| Median | 45.6 |
| 3rd quartile | 68.2 |
| Maximum | 137 |
| Disease stage at the initial diagnosis, n (%) | |
| I | 1 (2) |
| II | 20 (39) |
| III | 21 (41) |
| IV | 6 (12) |
| Unknown | 3 (6) |
| Prior anti-cancer therapy, n (%) | |
| Chemotherapy | 51 (100) |
| Anthracyclines | 51 (100) |
| Taxanes | 51 (100) |
| Trastuzumab | 51 (100) |
| Surgery | 46 (90) |
| Radiotherapy | 28 (55) |
| Endocrine therapy | 20 (39) |
| Vaccines | 0 |
| Immunotherapy | 0 |
| Duration from completion of trastuzumab, n (%) (weeks) | |
| <8 | 40 (78) |
| ≥8 | 11 (22) |
| Number of metastatic sites, n (%) | |
| ≥3 | 21 (41) |
| 2 | 19 (37) |
| 1 | 11 (22) |
| Visceral or nonvisceral metastatic, n (%) | |
| Visceral | 42 (82) |
| Nonvisceral | 9 (18) |
| Hormone receptor status, n (%) | |
| ER+ and/or PgR+ | 15 (29) |
| ER+ and PgR+ | 7 (14) |
| ER+ and PgR− | 8 (16) |
| ER− and PgR− | 35 (69) |
| Unknown | 1 (2) |
ER estrogen receptor, PgR progesterone receptor